Iloperidone: Does it have a meaningful place in therapy?

American Journal of Health-System Pharmacy

Volumn 68, Issue 4, 2011, Pages 297-

  Dopheide, Julie A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ILOPERIDONE; PROLACTIN; RISPERIDONE; ZIPRASIDONE;

CLINICAL PRACTICE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; LIVEWEIGHT GAIN; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 79956056297     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100500     Document Type: Editorial

References (4)

1. Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health-Syst Pharm. 2011; 68:301-8.
2. Volpi S, Potkin SG, Malholtra AK et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009; 70:801-9.
3. Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009; 14:1024-34.
4. Iloperidone (Fanapt): another second-generation antipsychotic. Med Lett Drugs Ther. 2010; 52:13-4.